TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived stem cell technology platform are currently in clinical development. - Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients. On July 4, 2016, we entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States. - Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis.  Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication. TiGenix is based in Leuven, Belgium, and has operations in Madrid, Spain.
Type
Public
HQ
Leuven, BE
Founded
2000
Size (employees)
65 (est)
TiGenix was founded in 2000 and is headquartered in Leuven, BE

TiGenix Office Locations

TiGenix has office in Leuven
Leuven, BE

TiGenix Online Presence

TiGenix Company Life

You may also be interested in